Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Study identifies prognostic value of IDH and CIC mutations for grade II/III glioma patients

Study identifies prognostic value of IDH and CIC mutations for grade II/III glioma patients

NRG Oncology investigators have identified two biomarkers that are prognostic of overall and progression-free survival for patients with lower-grade gliomas. [More]
IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Radiation therapy is the main treatment modality in the management of head and neck cancer. [More]
Researchers find better patient-reported quality of life in women who received pelvic IMRT

Researchers find better patient-reported quality of life in women who received pelvic IMRT

NRG Oncology investigators report better patient-reported quality of life measures for women who received intensity modulated radiation therapy (IMRT) for their pelvic radiation therapy (RT) than those who received standard RT. [More]
Immediate breast reconstruction can help avoid period of psychosocial distress linked to mastectomy

Immediate breast reconstruction can help avoid period of psychosocial distress linked to mastectomy

Immediate breast reconstruction (IBR) can avoid some of the psychological effects of undergoing mastectomy for breast cancer, compared to waiting for delayed breast reconstruction (DBR), reports a study in the October issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons. [More]
Study examines benefits of hormonal therapy for prostate cancer patients with prior history of heart attack

Study examines benefits of hormonal therapy for prostate cancer patients with prior history of heart attack

In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. [More]
Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Stereotactic body radiation therapy (SBRT) is a specialized and highly targeted method of delivering radiotherapy, or radiation therapy, to treat cancer. [More]
Study helps identify optimal treatment option for NSCLC patients with brain metastases

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment. [More]
Radiation boost provides added benefit to DCIS patients following breast-conserving surgery and WBRT

Radiation boost provides added benefit to DCIS patients following breast-conserving surgery and WBRT

A supplemental "boost" of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology. [More]
Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Increasing adoption of SBRT improves survival rates for older patients with early stage lung cancer

Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) rose from roughly 40 to 60 percent over the past decade, concurrent with the increasing adoption of SBRT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
IMRT reduces risk of side effects, improves quality of life for endometrial and cervical cancer patients

IMRT reduces risk of side effects, improves quality of life for endometrial and cervical cancer patients

Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
CNS experts create new research-based guidelines for evaluation and treatment of NFPAs

CNS experts create new research-based guidelines for evaluation and treatment of NFPAs

Nonfunctioning pituitary adenomas (NFPAs) are common benign tumors that may be present for years before causing any symptoms. [More]
Addition of chemotherapy to post-surgical radiation treatment improves survival in medulloblastoma patients

Addition of chemotherapy to post-surgical radiation treatment improves survival in medulloblastoma patients

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival. [More]
Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBRT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
SRS reduces likelihood of local recurrence of brain metastases in cancer patients

SRS reduces likelihood of local recurrence of brain metastases in cancer patients

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Researchers identify, validate three distinct molecular subtypes of prostate cancer

Researchers identify, validate three distinct molecular subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. [More]
Concord Medical's first proton therapy center to be installed at Beijing Proton Medical Center

Concord Medical's first proton therapy center to be installed at Beijing Proton Medical Center

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, is pleased to announce that its subsidiary, Medstar Leasing Co., Ltd, has signed a contract with IBA for the purchase, installation and maintenance of a proton therapy system, which will be installed at Beijing Proton Medical Center. [More]
Advertisement
Advertisement